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Surrogate of immunityThe generation of anti-streptococcal antibody during Streptococcus
pyogenes infection is known to afford serotype speciﬁc protection
against secondary infection, and to prevent growth of the organism in
the blood of convalescent donors (Lanceﬁeld, 1959). Inoculation of a
known quantity of S. pyogenes into donor whole blood and measure-
ment of the degree of multiplication over 3 h is a well-established
in vitro assay for S. pyogenes immunity that was ﬁrst described by
Edgar Todd in 1927 (Todd, 1927) and immortalised by Rebecca
Lanceﬁeld over subsequent decades (Lanceﬁeld, 1959). More recently,
the Lanceﬁeld assay has been modiﬁed for the screening of vaccine an-
tigens through supplementation of whole blood from healthy donors
with serum from vaccinated animals or humans (Caro-Aguilar et al.,
2013; Hu et al., 2002; Kotloff et al., 2004). A major barrier to use of the
Lanceﬁeld assay is the frequent existence of natural immunity to
S. pyogenes within the donor blood utilised. This necessitates the use
of blood from a signiﬁcant number of human donors, and/or pre-
screening for endogenous anti-streptococcal immunity prior to the
assay being conducted (Moreland et al., 2014; Bauer et al., 2012).
The Immunoglobulin G-degrading enzyme of S. pyogenes (IdeS) is a
secreted cysteine protease that cleaves human immunoglobulin (Ig)G
at the hinge region, preventing FcR recognition and phagocytic ingestion
of opsonised bacteria (von Pawel-Rammingen et al., 2002). The enzyme
promotes complete digestion of IgG in whole blood in a matter of mi-
nutes (Johansson et al., 2008), raising the possibility that it could be
exploited to facilitate inactivation of the endogenous anti-streptococcalglinski),
. This is an open access article underantibodies that prevent the use of some donor whole blood samples in
Lanceﬁeld assays. However, downstream detection of antibody in sam-
ples fromconvalescent patients and/or vaccinated subjectswould require
the enzyme to be inhibited following endogenous antibody digestion.
Alkylating agents such as iodoacetamide can inhibit IdeS-mediated IgG
cleavage (von Pawel-Rammingen et al., 2002) but are too cytotoxic for
use in a whole blood assay. As a solution, we hypothesised that the
commercially available, membrane-impermeable iodoacetamide deriva-
tive 4-Acetamido-4′-((iodoacetyl)amino)Stilbene-2,2′-Disulfonic Acid
(A484,Molecular Probes)would inhibit IdeSwithout promoting intracel-
lular alkylation; and thus allow the anti-streptococcal activity of exoge-
nously applied samples to be evaluated (Johnson, 2010).
Weﬁrst conﬁrmed that A484was capable of inhibiting the antibody-
cleaving activity of IdeS using the clinical pooled plasma product intra-
venous immunoglobulin (IVIG) as a source of puriﬁed immunoglobulin.
In 10mMTris–HCl (pH 8), 10mMA484was shown to effectively inhibit
0.5 μg of IdeS, and prevent the otherwise complete digestion of 2 μg of
IVIG in 1 h at 37 °C (Fig. 1A). The ability of IdeS to digest the endogenous
anti-streptococcal antibodies present within heparinised donor whole
blood was next determined by co-incubation of whole blood, from an
approved sub-collection of the Imperial College Tissue Bank, with IdeS
(6.25–200 μg/ml) or PBS for 1 h at 37 °C. Following IdeS treatment,
heat inactivated plasma (from each whole blood sample) was diluted
1:100, and anti-streptococcal antibody activities were measured by
ELISA using plates coatedwith overnightM1 S. pyogenes cultures (strain
H305) diluted to an OD600 of 0.5 in PBS as previously described
(Reglinski et al., 2016). Bound, intact antibodies were detected using a
1:20,000 dilution of Fc-speciﬁc, HRP-conjugated goat anti-human IgG.
An IdeS concentration of 25 μg/ml was shown to reduce the anti-S.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Establishing themodiﬁed Lanceﬁeld assay conditions. A) IdeS is inhibited by A484. 2 μg of IVIG (all lanes) was incubated with 0.5 μg of IdeS in presence of 10 mM iodoacetamide
(IAM), 10 mM A484 or PBS. Reactions were visualised by SDS-PAGE under non-reducing conditions. Molecular mass markers are given in kilodaltons. B and C) IdeS can reduce the anti-
streptococcal activity of whole blood but not in the presence of A484. Plasma from B) IdeS treated or C) IdeS/A484 treated blood samples (n = 3) were evaluated for anti-streptococcal
activity by ELISA. Grey shading represents the upper and lower OD450 values from wells incubated with PBS in place of plasma. Data: mean ± SD. D) Evaluation of A484 impact on
human neutrophils. Donor neutrophils (n = 3) were incubated with PBS (white bars), 2.5 mM A484 (grey bars) or 2.5 mM iodoacetamide (black bars) for 4 h, and the percentage of live,
apoptotic and dead neutrophils was determined by ﬂow cytometry following FITC-annexin V/PI staining. Data: mean ± SD. *p b 0.05, two-way ANOVA with Bonferroni's correction.
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tion (Fig. 1B).
To determine if the antibody-cleaving activity of IdeS could be
inhibited by A484 in whole blood, blood samples were co-incubated
with 25 μg/ml IdeS and A484 (2.5 mM–0.15625 mM) for 1 h at 37 °C,
and the ELISA repeated. IdeS activity was inhibited by 2.5 mM of A484
(Fig. 1C). To ensure that A484would not cause neutrophil death, freshly
isolated human neutrophils (puriﬁed from blood using MACSxpress®
Neutrophil Isolation Kit, Miltenyi Biotec) in PBS supplemented with
10% foetal bovine serum, were coincubated with A484 and then stained
using FITC-Annexin V Apoptosis Detection Kit I (BD Pharmingen). In
contrast to 2.5 mM iodoacetamide, 2.5 mM of A484 did not induce cell
death over the 4 h period required to complete the assay (Fig. 1D). To-
gether these data provided the necessary conditions for IdeS-mediated
ablation of endogenous anti-streptococcal antibody from donor whole
blood, and subsequent inhibition of IdeS with the non-cytotoxic
iodoacetamide derivative A484.
Having outlined the necessary conditions for selected endogenous
antibody digestion, Lanceﬁeld assays were performed using 270 μl of
whole blood from twelve different donors, and modiﬁed by addition
of 25 μg/ml of IdeS for 1 h, followed by 2.5 mM of A484 for 30 min. To
prepare the bacterial inoculum, overnight S. pyogenes (M1, strain
H305) cultures were inoculated 1:10 into fresh Todd-Hewitt broth
and incubated at 37 °C with 5% CO2 to an OD600 of 0.15–0.3. Cultures
were then diluted 1:5000 in PBS, to provide an inoculum of approxi-
mately 20–200 CFU in 15 μl, and plated to allow precise quantiﬁcation
of the starting inoculum. 15 μl of bacterial suspension was inoculated
into IdeS/A484-treated or sham-treatedwhole blood reactions, incubat-
ed for 3 h, then plated out in triplicate to allow enumeration of bacterial
survival (CFU ml−1(t = 3 h)/CFU ml−1(t = 0 h)). Compared with sham-
treated controls, IdeS/A484 treatment facilitated survival and growth
of S. pyogenes even in samples that had otherwise demonstrated endog-
enous bactericidal activity as a result of pre-existing immunity. Moreimportantly, the reagents substantially reduced the observed variation
in S. pyogenesmultiplication obtained from the twelve donors (Fig. 2A).
It was noted that the addition of A484 appeared to decrease the bac-
tericidal activity of donor samples, suggesting that the reagent may im-
pact on opsonophagocytic uptake; notwithstanding the lack of any
effect on neutrophil apoptosis. To explore this observation, puriﬁed
human neutrophils were adjusted to 2 × 106 cells/ml, pre-treated with
2.5 mM of A484 in the presence of IVIG or baby rabbit complement,
and co-incubated with Oregon Green 488-X, succinimidyl ester 6-
isomer (Molecular Probes) labelled GAS cells at a ratio of 10:1. After a
30 min co-incubation the percentage of neutrophils containing labelled
bacteria in the baby rabbit serum reactionswas reduced by approximate-
ly 30% in the presence of A484. In contrast, antibody mediated uptake
was unaffected by the presence of A484, suggesting that the reagent
may be speciﬁcally impacting on complement mediated uptake (Fig. 2B).
We next determined whether it was possible to detect anti-
S. pyogenes antibody activity in exogenous IVIG (2 mg/ml) when
added to the modiﬁed Lanceﬁeld whole blood reactions (Fig. 2C). IVIG
was able to signiﬁcantly limit M1 S. pyogenes growth, and, through ap-
plication of the modiﬁed Lanceﬁeld assay, this effect was apparent in
all donor samples. Finally we evaluated whether it was possible to de-
tect anti-S. pyogenes activity in convalescent serum obtained from a pa-
tient 21 d following recovery from invasive M4 S. pyogenes infection.
Although no increase in bacterial multiplication was observed upon
IdeS/A484 pre-treatment, the inter-donor variation was reduced sufﬁ-
ciently to demonstrate that convalescent patient serum, but not normal
human serum, was capable of promoting serotype speciﬁc killing of the
M4 strain H914, an invasive clinical isolate recovered from the blood of
the patient at the time of acute infection. In contrast, the same convales-
cent serum sample was unable to limit growth of a serotype M1 isolate,
highlighting both the serotype speciﬁcity of the antibody response to
S. pyogenes, and the potential applicability of the described protocol as
an in vitro surrogate-of-immunity assay (Fig. 2D and E).
Fig. 2. IdeS/A484modiﬁcation of Lanceﬁeld assay. A) Sequential addition of IdeS and A484 renders immune donor blood susceptible to streptococcal growth. Donor blood samples (n=
12) were pre-treated with IdeS and/or A484 and supplemented with 20–200 CFU of S. pyogenes (serotype M1 strain H305). Net bacterial growth (dashed line) was deﬁned by a
multiplication factor N1. B) A484 inhibits complement but not Ig-mediated opsonophagocytosis. Donor neutrophils (n = 3) were incubated with baby rabbit complement (BRC) or
IVIG in the presence of PBS (white bars), 2.5 mM A484 (grey bars) or 25 μg/ml IdeS (black bars) prior to the addition of 488+ GAS cells. The percentage of 488+ neutrophils was
determined by ﬂow cytometry. *p b 0.05, two-tailed student's t-test. C) IdeS/A484 treatment of donor whole blood (n = 8) permits detection of the anti-streptococcal activity of IVIG.
*p b 0.05, Wilcoxon matched-pairs signed rank test. D and E) Effect of 10% normal human serum (NHS) or convalescent antiserum from M4-infected patient (anti-M4) on growth of
strain H305 (M1, n = 6) or strain H914 (M4, n = 8) in a D) traditional Lanceﬁeld assay or E) modiﬁed Lanceﬁeld assay (IdeS/A484 pre-treatment of whole blood). *p b 0.05, Wilcoxon
matched-pairs signed rank test.
71M. Reglinski et al. / Journal of Microbiological Methods 124 (2016) 69–71In conclusion, pre-treatment of donor whole blood with the IgG
degrading enzyme IdeS successfully reduced the inter-donor variation as-
sociated with the Lanceﬁeld assay, and rendered immune whole blood
susceptible to S. pyogenes multiplication. Notwithstanding the non-
speciﬁc impact of A484 on complement mediated opsonophagocytosis,
the modiﬁed assay was capable of detecting serotype speciﬁc killing
using stored patient serum, thus facilitating retrospective dissection of
the bactericidal antibody response to S. pyogenes. While the method
will require further evaluation using a wider range of paired strains and
serum samples, it may prove beneﬁcial for determining the immune sta-
tus of populations during S. pyogenes outbreaks, or,more importantly as a
surrogate of immunity during vaccine trials.
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